Everything below concerns CJC-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Although rubidium is more abundant in Earth's crust than caesium, the limited applications and the lack of a mineral rich in rubidium limits the production of rubidium compounds to 2 to 4 tonnes per year. Several methods are available for separating potassium, rubidium, and caesium. The fractional crystallization of a rubidium and caesium alum (Cs,Rb)Al(SO4)2·12H2O yields after 30 subsequent steps pure rubidium alum. Two other methods are reported, the chlorostannate process and the ferrocyanide process. For several years in the 1950s and 1960s, a by-product of potassium production called Alkarb was a main source for rubidium. Alkarb contained 21% rubidium, with the rest being potassium and a small amount of caesium. Today the largest producers of caesium produce rubidium as a by-product from pollucite.
The Georgia Train and Equip Program (GTEP) was an American-sponsored 18-month, $64-million program aimed at increasing the capabilities of the Georgian armed forces by training and equipping four 600-man battalions with light weapons, vehicles and communications. The program enabled the US to expedite funding for the Georgian military for Operation Enduring Freedom. On 27 February 2002, the US media reported that the U.S. would send approximately two hundred United States Army Special Forces soldiers to Georgia to train Georgian troops. The program implemented President Bush's decision to respond to the Government of Georgia's request for assistance to enhance its counter-terrorism capabilities and addressed the situation in the Pankisi Gorge. The program was planned to be a 20-month long, $64 million effort. The move drew protests from many Russians. On 1 March 2002, in response to the domestic outcry, Russian president Vladimir Putin met with Georgian president Eduard Shevardnadze in Kazakhstan and pledged his support for the American military initiative. The program began in May 2002 when American special forces soldiers of the 10th Special Forces Group began training select units of the Georgian Armed Forces, including the 12th Commando Light Infantry Battalion, the 16th Mountain-Infantry Battalion, the 13th "Shavnabada" Light Infantry Battalion, the 11th Light Infantry Battalion, a mechanized company, and small numbers of Interior Ministry troops and border guards.
OSB's mechanical properties make it suitable for load-bearing applications in construction. In North America, it is more popular than plywood, commanding 66% of the structural panel market in 2016. The most common uses are as sheathing in walls, flooring, and roof decking. For exterior walls, panels are available with a radiant-barrier layer laminated to one side; this eases installation and increases energy performance of the building envelope. OSB is also used in furniture production.
Sources: en.wikipedia.org
==== Alternative mRNA editing ==== Alternative U-to-C mRNA editing was first reported in WT1 (Wilms Tumor-1) transcripts, and non-classic G-A mRNA changes were first observed in HNRNPK (heterogeneous nuclear ribonucleoprotein K) transcripts in both malignant and normal colorectal samples. The latter changes were also later seen alongside non-classic U-to-C alterations in brain cell TPH2 (tryptophan hydroxylase 2) transcripts. Although the reverse amination might be the simplest explanation for U-to-C changes, transamination and transglycosylation mechanisms have been proposed for plant U-to-C editing events in mitochondrial transcripts. A recent study reported novel G-to-A mRNA changes in WT1 transcripts at two hotspots, proposing the APOBEC3A (apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3A) as the enzyme implicated in this class of alternative mRNA editing. It was also shown that alternative mRNA changes were associated with canonical WT1 splicing variants, indicating their functional significance.
That turned into 'maybe we can fucking do this.' And that turned into this." In September 2008, it was announced that Alice in Chains would headline Australia's Soundwave Festival in 2009, alongside Nine Inch Nails and Lamb of God. In February 2009, it was also announced that Alice in Chains would play at the third annual Rock on the Range festival. On August 1, 2009, Alice in Chains performed, along with Mastodon, Avenged Sevenfold, and Glyder, at Marlay Park, Dublin as direct support to Metallica. The band made an appearance on Later... with Jools Holland on November 10, 2009, performing "Lesson Learned", "Black Gives Way to Blue", and "Check My Brain" as the final performance of the episode. To coincide with the band's European tour, Alice in Chains released its next single, "Your Decision", on November 16, 2009, in the UK and on December 1 in the US. The last single from the album was "Lesson Learned", and it was released to rock radio on June 22, 2010. Black Gives Way to Blue debuted at No. 5 on the Billboard 200. On May 18, 2010, the album was certified gold by the RIAA for selling over 500,000 copies in the U.S. The singles "Check My Brain" and "Your Decision" reached No. 1 on Billboard's Mainstream Rock Tracks, while "Lesson Learned" reached No. 4. "Check My Brain" was also the band's first No. 1 song on the Alternative Songs chart, and on the Hot Rock Songs chart, it also reached No. 92 on Billboard's Hot 100, becoming the band's first single to appear on the chart.
=== 2000–2006 === The years from 2000 to 2006 were bloody ones in Colombia with thousands of deaths every year resulting from the ongoing war between the Colombian Armed Forces, Paramilitary groups such as the AUC, and the rebel groups (mainly the FARC, ELN and the EPL). The fighting resulted in massive internal displacement of Colombia's civilian population and thousands of civilian deaths. During President Uribe's first term in office (2002–2006), the security situation inside Colombia showed some measure of improvement, and the economy, while still fragile, showed some positive signs of recovery, according to observers. However, relatively little had been accomplished in structurally solving the country's other grave problems, such as poverty and inequality, possibly in part due to legislative and political conflicts between the administration and the Colombian Congress (including those over a controversial project to eventually give Uribe the possibility of re-election) and a relative lack of freely allocated funds and credits. Some critical observers considered that Uribe's policies, while reducing crime and guerrilla activity, were too slanted in favor of a military solution to Colombia's internal war, while neglecting grave social and human rights concerns. Critics asked for Uribe's government to change this position and make serious efforts towards improving the human rights situation inside the country, protecting civilians, and reducing any abuses committed by the armed forces.
== Division of Public Health Information Dissemination == The Public Health Informatics Office (PHIO), formerly the Division of Public Health Information Dissemination is an interdisciplinary team that collaborates across the agency and with private and governmental partners to provide innovative data, analytics, and technology solutions for public health action.
Sources: en.wikipedia.org
Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease. Rivastigmine can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. Rivastigmine is eliminated through the urine, and appears to have relatively few drug-drug interactions. It was patented in 1985 and came into medical use in 1997.
=== Index of central obesity === Index of Central Obesity (ICO) is the ratio of waist circumference and height first proposed by Parikh et al. in 2007 as a better substitute to the widely used waist circumference in defining metabolic syndrome. The National Cholesterol Education Program Adult Treatment Panel III suggested cutoff of 102 cm (40 in) and 88 cm (35 in) for males and females as a marker of central obesity. The same was used in defining metabolic syndrome. Misra et al. suggested that these cutoffs are not applicable among Indians and the cutoffs be lowered to 90 cm (35 in) and 80 cm (31 in) for males and females. Various race specific cutoffs were suggested by different groups. The International Diabetes Federation defined central obesity based on these various race and gender specific cutoffs. The other limitation of waist circumference is that the measurement procedure has not been standardized and in children there are no, or few, comparison standards or reference data. Parikh et al. looked at the average heights of various races and suggested that by using ICO various race- and gender-specific cutoffs of waist circumference can be discarded. An ICO cutoff of 0.53 was suggested as a criterion to define central obesity. Parikh et al. further tested a modified definition of metabolic syndrome in which waist circumference was replaced with ICO in the National Health and Nutrition Examination Survey (NHANES) database and found the modified definition to be more specific and sensitive.
Column chromatography takes a long time. Many manufacturers like Biotage, Buchi, Interchim and Teledyne Isco have developed automated flash chromatography systems that minimize human involvement in the purification process. Such systems are typically referred to as low pressure liquid chromatography (LPLC). They include components normally found on more expensive high pressure liquid chromatography (HPLC) systems such as a gradient pump, sample injection ports, a UV detector and a fraction collector to collect the eluent, but operating at a lower pressure (usually 350–525 kPa or 50.8–76.1 psi). Typically these automated systems can separate samples from a few milligrams up to an industrial many kilogram scale, and are cheaper and faster than doing multiple injections on preparative HPLC systems. The resolution (or the ability to separate a mixture) of an LPLC system is lower, as the packing material in an HPLC column can be much smaller, typically only 5 micrometre. This increases the stationary phase surface for interactions, and gives better separation. However, small packing media causes the high back pressure, thus "high pressure" liquid chromatography The LPLC columns are typically packed with silica of around 50 micrometres, thus reducing back pressure and resolution, but it also removes the need for expensive high pressure pumps. Manufacturers are now starting to move into higher pressure flash chromatography systems, which operate above 1 MPa (150 psi), calling them "medium pressure liquid chromatography" (MPLC).
== Catabolism == NAAG is catabolized via NAAG peptidase activity. Two enzymes with NAAG peptidase activity have been cloned, glutamate carboxypeptidase II and glutamate carboxypeptidase III. These enzymes mediate the hydrolysis of NAAG to NAA and glutamate. Their inhibition can produce therapeutic benefits. Two main types of inhibitors of this enzyme are known: compounds related to 2-(phosphonomethyl)pentanedioic acid (2-PMPA) and urea-based analogs of NAAG, including ZJ43, ZJ17, and ZJ11. In rat models, ZJ43 and 2-PMPA reduce perception of inflammatory and neuropathic pain when administered systemically, intracerebrally, or locally, suggesting that NAAG modulates neurotransmission in pain circuits via mGlu3 receptors. The inhibition of NAAG hydrolysis increases the concentration of NAAG in the synaptic space analogous to the effects of MAOIs in increasing the concentration of serotonin. This elevated NAAG gives greater activation of presynaptic mGluR3 receptors, which decrease release of transmitter (glutamate) in the pain signaling pathways of the spinal cord and brain. In the case of traumatic brain injury, the injection of a NAAG peptidase inhibitor reduces neuron and astrocyte death in the hippocampus nearest the site of the injury. In a mouse model of amyotrophic lateral sclerosis (ALS), the chronic inhibition of NAAG peptidase activity delayed the onset of ALS symptoms and slowed the progress of the neuronal death.
== Refining the techniques == The next development was gas chromatography (GC). Martin and Synge had predicted its principles in their 1941 paper. Erika Cremer laid the theoretical basis of GC in 1944. Austrian chemist Fritz Prior, under the direction of Erika Cremer, constructed in 1947 the first prototype of a gas chromatograph and achieved separating oxygen and carbon dioxide, in 1947 during his Ph.D. research. Beginning in 1949, Martin and Anthony T. James worked on developing GC. At his 1952 Nobel lecture, Martin announced the successful separation of a wide variety of natural compounds by GC. GC was quickly adopted since it is easy and efficient for separating organic chemicals, and new detection methods for analyzing the output were quickly developed. The thermal conductivity detector, described in 1954 by N. H. Ray, was the foundation for several other methods: the flame ionization detector by J. Harley, W. Nel, and V. Pretorius in 1958, and the electron capture detector by James Lovelock in 1958. Others introduced mass spectrometers to gas chromatography in the late 1950s. The work of Martin and Synge also set the stage for high performance liquid chromatography (HPLC), suggesting that small sorbent particles and pressure could produce fast liquid chromatography techniques. This became widely practical by the late 1960s (and the method was used to separate amino acids as early as 1960).
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.